Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response

Affiliations

¹ Department of Virology, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) UMR_S 1085, Rennes, France.
² Department of Hepatology, CRI, INSERM, UMR 1149, AP-HP Hôpital Beaujon, Université de Paris, Clichy, France.

Editorial

Vincent Thibault et al. Aliment Pharmacol Ther. 2021 Feb.

. 2021 Feb;53(4):552-554.

doi: 10.1111/apt.16214.

¹ Department of Virology, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) UMR_S 1085, Rennes, France.
² Department of Hepatology, CRI, INSERM, UMR 1149, AP-HP Hôpital Beaujon, Université de Paris, Clichy, France.

No abstract available

Comment in

Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response. Authors' reply.
Brakenhoff SM, de Man RA, de Knegt RJ, Janssen HLA, Sonneveld MJ. Brakenhoff SM, et al. Aliment Pharmacol Ther. 2021 Feb;53(4):555-556. doi: 10.1111/apt.16233. Aliment Pharmacol Ther. 2021. PMID: 33616982 No abstract available.

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Brakenhoff SM, de Man RA, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. Brakenhoff SM, et al. Aliment Pharmacol Ther. 2021 Jan;53(2):314-320. doi: 10.1111/apt.16172. Epub 2020 Nov 21. Aliment Pharmacol Ther. 2021. PMID: 33222190 Free PMC article.

1. Asselah T, Loureiro D, Boyer N, et al. Targets and future direct‐acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4:883‐892.
1. Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73:409‐422.
1. Brakenhoff SM, de Man RA, Boonstra A, et al. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Aliment Pharmacol Ther. 2021;53:314‐320 .
1. Lin C‐L, Kao J‐H. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2016;22:423‐431.
1. Martinot‐Peignoux M, Lapalus M, Maylin S, et al. Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘‘precision medicine” in HBeAg‐negative chronic hepatitis B patients. J Viral Hepat. 2016;23:905‐911.